These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 15605207)

  • 21. The Role of Angiogenesis Factors in the Formation of Vascular Changes in Scleroderma by Assessment of the Concentrations of VEGF and sVEGFR2 in Blood Serum and Tear Fluid.
    Waszczykowska A; Goś R; Waszczykowska E; Dziankowska-Bartkowiak B; Podgórski M; Jurowski P
    Mediators Inflamm; 2020; 2020():7649480. PubMed ID: 32410862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis.
    D'Alessio S; Fibbi G; Cinelli M; Guiducci S; Del Rosso A; Margheri F; Serratì S; Pucci M; Kahaleh B; Fan P; Annunziato F; Cosmi L; Liotta F; Matucci-Cerinic M; Del Rosso M
    Arthritis Rheum; 2004 Oct; 50(10):3275-85. PubMed ID: 15476218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1.
    Allanore Y; Borderie D; Lemaréchal H; Ekindjian OG; Kahan A
    Arthritis Res Ther; 2004; 6(4):R309-14. PubMed ID: 15225366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreased expression of the endothelial cell-derived factor EGFL7 in systemic sclerosis: potential contribution to impaired angiogenesis and vasculogenesis.
    Manetti M; Guiducci S; Romano E; Avouac J; Rosa I; Ruiz B; Lepri G; Bellando-Randone S; Ibba-Manneschi L; Allanore Y; Matucci-Cerinic M
    Arthritis Res Ther; 2013 Oct; 15(5):R165. PubMed ID: 24286167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proangiogenic hematopoietic cells of monocytic origin: roles in vascular regeneration and pathogenic processes of systemic sclerosis.
    Yamaguchi Y; Kuwana M
    Histol Histopathol; 2013 Feb; 28(2):175-83. PubMed ID: 23275301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proangiogenic effects of soluble α-Klotho on systemic sclerosis dermal microvascular endothelial cells.
    Mazzotta C; Manetti M; Rosa I; Romano E; Blagojevic J; Bellando-Randone S; Bruni C; Lepri G; Guiducci S; Ibba-Manneschi L; Matucci-Cerinic M
    Arthritis Res Ther; 2017 Feb; 19(1):27. PubMed ID: 28183357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The vascular perspective of systemic sclerosis: of chickens, mice and men.
    Sgonc R
    Int Arch Allergy Immunol; 1999 Nov; 120(3):169-76. PubMed ID: 10592461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deletion of FHL2 gene impaired ischemia-induced blood flow recovery by modulating circulating proangiogenic cells.
    Huang PH; Chen CY; Lin CP; Wang CH; Tsai HY; Lo WY; Leu HB; Chen JW; Lin SJ; Chu PH
    Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):709-17. PubMed ID: 23413425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Scleroderma dermal microvascular endothelial cells exhibit defective response to pro-angiogenic chemokines.
    Tsou PS; Rabquer BJ; Ohara RA; Stinson WA; Campbell PL; Amin MA; Balogh B; Zakhem G; Renauer PA; Lozier A; Arasu E; Haines GK; Kahaleh B; Schiopu E; Khanna D; Koch AE
    Rheumatology (Oxford); 2016 Apr; 55(4):745-54. PubMed ID: 26705326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of the angiogenic phenotype of normal and systemic sclerosis endothelial cells by gain-loss of function of pentraxin 3 and matrix metalloproteinase 12.
    Margheri F; Serratì S; Lapucci A; Chillà A; Bazzichi L; Bombardieri S; Kahaleh B; Calorini L; Bianchini F; Fibbi G; Del Rosso M
    Arthritis Rheum; 2010 Aug; 62(8):2488-98. PubMed ID: 20506099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of the Thromboxane A2 Receptor by 8-Isoprostane Inhibits the Pro-Angiogenic Effect of Vascular Endothelial Growth Factor in Scleroderma.
    Tsou PS; Amin MA; Campbell PL; Zakhem G; Balogh B; Edhayan G; Ohara RA; Schiopu E; Khanna D; Koch AE; Fox DA
    J Invest Dermatol; 2015 Dec; 135(12):3153-3162. PubMed ID: 26288351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defective vasculogenesis in systemic sclerosis.
    Kuwana M; Okazaki Y; Yasuoka H; Kawakami Y; Ikeda Y
    Lancet; 2004 Aug 14-20; 364(9434):603-10. PubMed ID: 15313361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin.
    Mackiewicz Z; Sukura A; Povilenaité D; Ceponis A; Virtanen I; Hukkanen M; Konttinen YT
    Clin Exp Rheumatol; 2002; 20(5):641-6. PubMed ID: 12412194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripheral blood mononuclear cells from patients with systemic sclerosis spontaneously secrete increased amounts of vascular endothelial growth factor (VEGF) already in the early stage of the disease.
    Bielecki M; Kowal K; Lapinska A; Chwiesko-Minarowska S; Chyczewski L; Kowal-Bielecka O
    Adv Med Sci; 2011; 56(2):255-63. PubMed ID: 21983449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abnormal amplitude and kinetics of digital postocclusive reactive hyperemia in systemic sclerosis.
    Gaillard-Bigot F; Roustit M; Blaise S; Gabin M; Cracowski C; Seinturier C; Imbert B; Carpentier P; Cracowski JL
    Microvasc Res; 2014 Jul; 94():90-5. PubMed ID: 24990822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis.
    Riccieri V; Stefanantoni K; Vasile M; Macrì V; Sciarra I; Iannace N; Alessandri C; Valesini G
    Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S46-52. PubMed ID: 21586218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP-12-dependent cleavage of the endothelial cell urokinase receptor.
    Serratì S; Cinelli M; Margheri F; Guiducci S; Del Rosso A; Pucci M; Fibbi G; Bazzichi L; Bombardieri S; Matucci-Cerinic M; Del Rosso M
    J Pathol; 2006 Oct; 210(2):240-8. PubMed ID: 16917801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brief report: impaired in vivo neovascularization capacity of endothelial progenitor cells in patients with systemic sclerosis.
    Kuwana M; Okazaki Y
    Arthritis Rheumatol; 2014 May; 66(5):1300-5. PubMed ID: 24782187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating endothelial progenitor cells in systemic sclerosis: relation to impaired angiogenesis and cardiovascular manifestations.
    Nevskaya T; Bykovskaia S; Lyssuk E; Shakhov I; Zaprjagaeva M; Mach E; Ananieva L; Guseva N; Nassonov E
    Clin Exp Rheumatol; 2008; 26(3):421-9. PubMed ID: 18578963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis.
    Beyer C; Schett G; Gay S; Distler O; Distler JH
    Arthritis Res Ther; 2009; 11(2):220. PubMed ID: 19473554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.